Nicox S.a.

Merck Sharp + Dohme Corp.

Allecra Therapeutics Sas

Nicox Science Ireland

Nicox

Stefano Biondi

Ennio Ongini

Nicoletta Almirante

Francesca Benedini

Amjad Ali

Silvia Stefanini

Michael Man-Chu Lo

Iyassu Sebhat

Laura Storoni

Christopher L Franklin

Valerio Chiroli

Wesley Kwan Mung Chong

Marco Forzatti

Alessia Nicotra

Annalisa Bonfanti

Rebecca Steele

Fabio Nicoli

Ravi P Nargund

Dong-Ming Shen

Kathleen M Rupprecht

Lin Yan

Robert K Baker

Pei Huo

Giovanni Fogliato

Yi Yang

Iyassu K Sebhat

William Vernier

Liming Dong

Francesco Impagnatiello

Chris Franklin

Massimiliano Ferrario

Achim Hans-Peter Krauss

Ganesh Prasanna

Andrea Faini

Julio Lazaro Padron

Alessandro Lamonica

Wesley Kwan Chong

William Francois Vernier

Achim Hans-Pter Krauss

A crystalline compound of formula (I):  The compound of formula (I) is a &#x3b2;-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.

Crystalline beta-lactamase inhibitor

A method of forming a compound of formula (IIIa):  

Method of forming methyl penam derivatives

The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metabolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.

Nitric oxide donor compounds

The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea.

Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology

The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereofR&#x2014;(Z)&#x2014;R&#x2003;&#x2003;(I)wherein R is the corticosteroid residue of formula (II): wherein:  The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.

Nitric oxide releasing steroids

A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) &#x2014;C(R1R2) (C(R3R4))0-1Y1R5, and 3) &#x2014;C(R1R2)&#x2014;O&#x2014;Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the group consisting of C(O)&#x2014;O&#x2014; and P(O)(OR6)&#x2014;O&#x2014;; and R6 is hydrogen or CH3, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. 

Angiotensin II receptor antagonists

A compound having the structure wherein R is an angiotensin receptor antagonist active group, and Y is provided that when Y is &#x2014;C(O)(CH)R, then R is 

A compound having the structureR&#x2014;Y  

A compound having the structure wherein or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.

Cicletanine derivatives

Nitroderivatives of prostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Nitric oxide donating prostamides

The invention relates to nitric oxide donors of the formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: wherein A and A' are independently selected from the group consisting of H and &#x2014;(X)&#x2014;Y with the proviso that at least one of A or A&#x2032; is not H;wherein  The invention also provides novel compositions comprising at least one compound of the invention and at least one therapeutic agent.

The present invention relates to alpha2-adrenergic receptor agonist nitrooxyderivatives, including the following structure, having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of ocular diseases, in particular high intraocular pressure and glaucoma.

Quinoxaline derivatives of alpha-2 adrenergic agonists

Growing community of inventors

Pero, Italy

Stefano Biondi